Nxera To Receive Us$4.8 Mn In Milestone Payments Following Centessa's Initiation Of Clinical Development Of Orx142, A Novel Ox2r Agonist
July 4 (Reuters) - Centessa Pharmaceuticals PLC 260y.F: NXERA PHARMA CO LTD: NXERA TO RECEIVE US$4.8 MN IN MILESTONE PAYMENTS FOLLOWING CENTESSA'S INITIATION OF CLINICAL DEVELOPMENT OF ORX142, A NOVEL OX2R AGONIST Source text: ID:nTSsc7c084 Further company coverage: [260y.F] (Reporting by Tokyo Newsroom) ((+81345201189;))
Recent news on Nxera Pharma
See all newsNxera Pharma Submits Marketing Authorization Application For Vamorolone In South Korea For Treatment Of Duchenne Muscular Dystrophy
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Nxera Pharma - Entered Into Exclusive License, Supply And Commercialization Agreement With Synmosa For Quviviq Across Eight Asia-Pacific Markets
Brief: Nxera Announces Successful Resolution Of Minig Patent Infringement Action
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up